Illumina Genome Analyzer II

描述（由申请人提供）：本提案的目的是通过收购Illumina Genome Analyzer IIx下一代DNA测序仪，大幅增强范德比尔特大学医学中心已建立的高产基因组技术核心（GTC）的测序能力。GTC成立于2008年，是由个性化医学办公室管理的机构核心设施，其任务是支持范德比尔特研究人员及其合作者的基因组需求。一个单一的Illumina基因组分析仪仪器，必要的工作人员和辅助设备购买或支持机构的资金。自成立以来，GTC迅速实施了许多技术和应用程序，以建立可靠和强大的高性能测序服务。这一努力的迅速成功导致我们的单一仪器几乎得到充分利用，导致新项目的等待时间很长。开发此应用程序是为了解决GTC工作人员确定的两个重要问题。首先，本申请中列出的主要用户代表了一组目前未得到支持的拟议仪器的重度用户（3年内预计利用率超过75%），强调了对额外测序能力的需求。其次，许多研究者正在利用配对末端和更长的读取长度测序运行来实现每个样品的更高测序覆盖率。这些较长的读数和配对末端方法需要显著更长的仪器运行时间，对现有仪器施加了进一步的压力。总之，这些问题为该应用程序支持GTC中的其他Illumina仪器提供了强有力的理由。GTC非常成功地支持了利用现有仪器的各种研究人员，并在Illumina平台上实施和优化了技术协议和生物信息学工具。这一成功将进一步加强额外的仪器，使GTC有效地支持一个更大的组NIH资助的研究人员。GTC的持续成功将得到强有力的机构承诺和极其熟练的生物信息学能力的保证。

DESCRIPTION (provided by applicant): The objective of this proposal is to substantially enhance the sequencing capabilities of the established and highly productive Genome Technology Core (GTC) at Vanderbilt University Medical Center through the acquisition of an Illumina Genome Analyzer IIx next-generation DNA sequencer. The GTC was founded in 2008 as an institutional core facility managed by the Office of Personalized Medicine and tasked with supporting the genomic needs of Vanderbilt investigators and their collaborators. A single Illumina Genome Analyzer instrument, necessary staff and secondary equipment were purchased or supported with institutional funds. Since its founding, the GTC has swiftly implemented a number of technologies and applications to establish a reliable and robust high-performance sequencing service. The rapid success of this effort has resulted in the near full utilization of our single instrument leading to long wait times for new projects. This application has been developed to address two vital issues identified by the staff of the GTC. First, the major users listed in this application represent a group of heavy users of the proposed instrument (more than 75% projected utilization for 3 years) that are not currently being supported, underscoring the need for additional sequencing capacity. Second, many investigators are utilizing paired end and longer read length sequencing runs to achieve higher sequencing coverage for each sample. These longer reads and paired end approaches require substantially longer instrument run times, putting further pressure on the existing instrumentation. Together, these issues provide a strong justification for this application to support an additional Illumina instrument in the GTC. The GTC has been extremely successful in supporting a diverse group of investigators that have made use of the existing instrumentation and in implementing and optimizing technical protocols and bioinformatic tools on the Illumina platform. This success will be further enhanced by the additional instrumentation to allow the GTC to efficiently support a larger group of NIH funded investigators. The continued success of the GTC will be assured by the strong institutional commitments, and extremely proficient bioinformatic capabilities.